The mean accumulated costs produced by type 2 diabetes per patient at 10 and 20 years is 2,302.51 USD and 4,398.7 USD, respectively.4 There are currently 12 medication groups approved for the management of diabetes and some of them have been associated with significant gastrointestinal adverse effects
Tirzepatide, sold as Mounjaro, is a newer medicine often compared with semaglutide
Wegovy (semaglutide) activates GLP-1 only and has a longer real-world track record
Genevas physicians help patients determine whether Tirzepatides dual pathway activity is the best fit for their metabolic needs and comfort level
10%15% potential weight loss Mounjaro (tirzepatide): originally FDA-approved for type 2 diabetes but prescribed off-label for weight loss
HO-1 mediates catalytic breakdown of heme, a potent pro-oxidant and pro-inflammatory molecule 465